UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Introduction

Type 2 Glycoprotein (GP2) is a quantitatively predominant membrane protein of excretory granules of pancreatic acinar cells. In a number of studies, it has been demonstrated that this protein is the main antigen for pancreatic antibodies associated with Crohn's disease Zonulin – a protein that can reversibly increase the permeability of the intestinal wall by changing the structure of tight junctions of the lateral surfaces of intestinal epithelial cells. The determination of fecal zonulin is used for noninvasive assessment of increased intestinal permeability. Normal values of fecal zonulin (≤ 110 ng/ml) indicate the absence of damage to the villous surface of the intestinal mucosa and normal density of intercellular contacts

Aims & Methods

The aim of the study was to establish the dependence of the level of type 2 glycoprotein on the level of fecal zonulin (FZ) in the feces of CD patients with exacerbation of the disease.
Material and methods. 217 patients with CD in remission of the disease (Ме age — 38 years) were examined. FZ was evaluated by ELISA (IDK ® Zonulin ELISA Kit, Immunodiagnostik AG, Germany) in ng/ml. Reference values: < 83.15 ng/ml - a variant of the norm, 83.15-110 ng/ml - an elevated level, 110 ng/ml - a high level.
The level of IgG and IgA to GP2 (antibodies to glycoprotein) antigen of pancreatic centroacinar cells (Anti-GP2, IgG, IgA) was determined by ELISA. Reference values: IgG GP-2 less than 10 units/ml, Ig And GP-2 less than 5 units/ml – positive values.

Results

In the stool samples of CD patients during remission in 76 (35%) patients, an increase in the FZ was detected, the average value was 235.4±11.6 ng/ml. In the blood samples of 59 (27.2%) CD patients during remission, an increase in Ig A GP-2 was detected, the average value was 24.4±1.9 units/ml. In the blood samples of 137 CD patients during remission, an increase in Ig G GP-2 was detected, the average value was 19.7±1.1 units/ml. There is no correlation between the concentration of FZ and the concentration of Ig A GP-2 (r-0.260) (p>0.05). There is a moderate correlation force (r-0.310) (p=0.033) between the concentration of FZ and the concentration of Ig G GP-2.

Conclusion

There is no correlation between the concentration of FZ in the feces of CD patients during remission with the concentration of Ig A GP-2 and Ig G GP-2 in the blood serum of patients.

THE DEPENDENCE OF THE CONCENTRATION OF TYPE 2 GLYCOPROTEIN ON THE CONCENTRATION OF ZONULIN IN CROHN'S DISEASE DURING REMISSION OF THE DISEASE

Anna Kagramanova 1, Oleg Knyazev 2, Alexandr Novikov 1, Elena Alexandrova 1, Bella Nanaeva 3, Raisa Gudkova 1, Dmitriy Kulakov 1, Asfold Parfenov 1

1 Moscow Clinical Scientific Center named after A.S. Loginov, Moscow, Russian Federation

2 Moscow Clinical Scientific Center named after A.S. Loginov, Moscow, Russian Federation|||State Scientific Centre of Coloproctology named after A.N. Ryzhyh, Moscow, Russian Federation

3 State Scientific Centre of Coloproctology named after A.N. Ryzhyh, Moscow, Russian Federation

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

UEG Podcast Episode

Journal Podcast

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease

Haluk Tarik Kani 1, Samuel Raimundo Fernandes 2

1 Department of Gastroenterology, Marmara University, School Of Medicine, Istanbul, Turkey

2 Centro Hospitalar Lisboa Norte, Lisbon, Portugal

Topics

IBD

Published

2023

UEG Online Course

accredited

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Perianal Crohn’s disease is a perianal complication of Crohn’s disease. It consists of inflammation near the anus in the form of skin tags, fistulas, abscesses and fissures. Affecting almost one in four Crohn’s patients, perianal Crohn’s disease needs to be assessed and treated in a multidisciplinary fashion.

This online course covers the definition and epidemiology of perianal Crohn’s disease. The diagnosis and assessment are divided into symptoms, clinical assessment and examination under anaesthesia. Various perianal Crohn’s disease treatment options are introduced, from initial medical to surgical management.

The course included comprehensive PPT slides and bespoke video presentations by Peter Irving and Amy Lightner, filmed in London and the United States in 2022. The combined material has a total duration of approximately 50 minutes. The estimated time needed to complete the course, including the final assessment, is 60 minutes.

Target audience

This course is suitable for gastroenterologists in training but is also appropriate for physicians and surgeons in other disciplines, as well as IBD clinical nurse specialists.

Perianal Crohn's disease

Peter Irving, Amy Lightner

Event

Perianal Crohn's disease

Topics

IBD Surgery

Accreditation status

accredited

Duration

1 hour

Published

2023

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Stricturing Crohn's disease

Jimme Klaas Wiggers 1

1 Academisch Med. Centrum Amsterdam, Amsterdam, Netherlands

Event

UEG Postgraduate Teaching Programme Vienna 2024

Topics

Education & Training IBD Immunology Mechanisms & Personalised Medicine Surgery

Session

Decision time in IBD: Difficult cases

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Fistulising Crohn's disease: Underlying mechanism

Judy Chou 1

1 Icahn School of Medicine at Mount Sinai, New York, United States of America

Event

UEG Week Berlin 2025

Topics

IBD Primary Care Surgery

Session

Disease primer: From inflammation to restoration - wound healing in IBD

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Type 2 glycoprotein (GP2) is a quantitatively predominant membrane protein of excretory granules of pancreatic acinar cells. In a number of studies, it has been demonstrated that this protein is the main antigen for pancreatic antibodies associated with Crohn's disease (CD). Zonulin – a protein that can reversibly increase the permeability of the intestinal wall by changing the structure of tight junctions of the lateral surfaces of intestinal epithelial cells. The determination of fecal zonulin is used for noninvasive assessment of increased intestinal permeability. Normal values of fecal zonulin (≤ 110 ng/ml) indicate the absence of damage to the villous surface of the intestinal mucosa and normal density of intercellular contacts.

Aims & Methods

The aim of the study was to establish the dependence of the level of type 2 glycoprotein on the level of fecal zonulin (FZ) in the feces of CD patients with exacerbation of the disease.
Material and methods. 122 patients with CD in the form of ilekolitis with exacerbation of the disease (Me age — 32 years) were examined. FZ was evaluated by ELISA (IDK ® Zonulin ELISA Kit, Immunodiagnostik AG, Germany) in ng/ml. Reference values: < 83.15 ng/ml is a variant of the norm, 83.15-110 ng/ml is an elevated level, 110 ng/ml is a high level.
The level of IgG and IgA to GP2 (antibodies to glycoprotein) antigen of pancreatic centroacinar cells (Anti-GP2, IgG, IgA) was determined by ELISA. Reference values: IgG GP-2 less than 10 units/ml, Ig and GP-2 less than 5 units/ml – positive values.

Results

In the stool samples of CD patients during the period of exacerbation in 92 (75,4%) patients, an increase in FZ was detected, the average value was 333.4 ±16.9 ng/ml. In the blood samples of 81 (66,4%) patients with CD during the period of exacerbation, an increase in Ig A GP-2 was detected, the average value was 43.4±6.9 units/ml. In the blood samples of 107 CD patients during the period of exacerbation, an increase in Ig G GP-2 was detected, the average value was 17.1 ± 1.3 units/ml. There is a high correlation force between the concentration of FZ and the concentration of Ig A GP-2 (r-0.760) (p=0.010). There is a moderate correlation force (r-0.490) (p=0.023) between the concentration of FZ and the concentration of Ig G GP-2.

Conclusion

An increase in the concentration of FZ in the feces of CD patients during exacerbation significantly correlates with an increase in the concentration of Ig A GP-2 and Ig G GP-2.

THE DEPENDENCE OF THE LEVEL OF GLYCOPROTEIN TYPE 2 ON THE LEVEL OF ZONULIN IN CROHN'S DISEASE

Anna Kagramanova 1, Oleg Knyazev 2, Albina Lishchinskaya 1, Raisa Gudkova 1, Karina Noskova 1, Elena Alexandrova 1, Alexandr Novikov 1, Alexandra Demchenko 1, Bella Nanaeva 3, Asfold Parfenov 1

1 Moscow Clinical Scientific Center named after A.S. Loginov, Moscow, Russian Federation

2 Moscow Clinical Scientific Center named after A.S. Loginov, Moscow, Russian Federation|||State Scientific Centre of Coloproctology named after A.N. Ryzhyh, Moscow, Russian Federation

3 State Scientific Centre of Coloproctology named after A.N. Ryzhyh, Moscow, Russian Federation